about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Vi­da Ven­tures co-leads Dyne's $115M megaround for next-gen oli­go ther­a­pies aimed square­ly at mus­cles

5 years ago
Financing

Covid-19 roundup: Cure­Vac beefs up its uni­corn IPO dreams as bil­lion­aire own­er takes this Covid-19 mR­NA play­er on a ...

5 years ago
Outsourcing
Pharma

Ab­b­Vie set­tles in­sur­ance fraud suit, agrees to tweak nurse am­bas­sador pro­gram; CStone aims for NSCLC OK with pos­i­tive ...

5 years ago
News Briefing

FDA takes the lead on defin­ing es­sen­tial un­der Trump's 'Buy Amer­i­can' ex­ec­u­tive or­der — as phar­ma warns of sup­ply ...

5 years ago
Outsourcing
Pharma

Re­gen­eron adds more pos­i­tive PhI­II da­ta for its NGF pro­gram — but safe­ty is still a big con­cern

5 years ago
R&D

Ver­sant de­buts Ridge­line's start­up #4, armed with $30M and al­ter­na­tive TCR cell ther­a­pies for sol­id tu­mors

5 years ago
Financing
Startups

Deep tech, round 2: DCVC Bio bags $350M fund to chase the tip of the life sci­ence spear

5 years ago
Financing

Covid-19 roundup: FDA com­mis­sion­ers call for more ‘con­cert­ed ef­fort’ on con­va­les­cent plas­ma R&D; Re­gen­eron boosts ...

5 years ago
Coronavirus

OWS' Mon­cef Slaoui lam­basts ‘in­sult­ing’ me­dia cov­er­age: 'How are you help­ing in this pan­dem­ic?'

5 years ago
Coronavirus

Sanofi un­der for­mal in­ves­ti­ga­tion for De­pakine al­le­ga­tions; Beam li­cens­es CAR-T tech from Ox­ford Bio­med­ica

5 years ago
News Briefing

Days af­ter seal­ing Sanofi pact, Kymera beats a path to the Nas­daq with $100M IPO pitch

5 years ago
Financing

CAR-T fil­ing in sight, Frank Zhang grabs full con­trol of J&J-part­nered Leg­end Biotech, steps down from Gen­Script

5 years ago
People
China

Brigham and Wom­en's pres­i­dent Eliz­a­beth Nabel fol­lows Mon­cef Slaoui off Mod­er­na's board

5 years ago
People
Coronavirus

Covid-19 roundup: Roger Perl­mut­ter hus­tles up hu­man vac­cine tri­als as Mer­ck looks to catch up on Covid-19; Chi­na ...

5 years ago
Coronavirus

No­var­tis turns to Sang­amo with a $795M-plus deal aimed at us­ing zinc fin­ger tech for the neu­ro pipeline

5 years ago
Deals

Covid-19 roundup: J&J gives deep­est look yet at vac­cine; As­traZeneca shies away from dis­cussing vac­cine com­mer­cial ...

5 years ago
Coronavirus

'Ex­quis­ite con­trol': Flag­ship pulls off $85M ral­ly around Omega Ther­a­peu­tic­s' clin­i­cal push for epi­ge­net­ic ...

5 years ago
Financing
Startups

Three years af­ter leav­ing Bio­gen, Alp­na Seth takes the spot­light with $73M for her neu­ro start­up

5 years ago
Financing
Startups

Covid-19 roundup: Mod­er­na re­moved signs around its man­u­fac­tur­ing plant — is it a tar­get for hack­ers?

5 years ago
Coronavirus

Pfiz­er/BioN­Tech makes sur­prise choice in fi­nal dash to Oc­to­ber fin­ish line for Covid-19 vac­cine

5 years ago
Coronavirus

Covid-19 roundup: Pe­ter Kolchin­sky’s RA Cap­i­tal spear­heads 'Covid Apol­lo,' a VC search for the best test; Up­start ...

5 years ago
Coronavirus

Can prog­en­i­tor cells go fur­ther than gene ther­a­py in reti­nal dis­or­ders? A biotech's an­swer shines in PhI­Ib

5 years ago
R&D
Cell/Gene Tx

As­traZeneca mines an­oth­er $6B ADC from Dai­ichi Sankyo, with block­buster am­bi­tions to ‘re­de­fine treat­ment ...

5 years ago
Deals

No­var­tis, Gilead, GSK grab pos­i­tive CHMPs; Menar­i­ni and Ra­dius sign up to $350M part­ner­ship

5 years ago
News Briefing
First page Previous page 69707172737475 Next page Last page
A service from the Financial Times